Please contact our sales representative to learn more information about this reagents.
Background
Otlertuzumab (TRU- 016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer. This drug was developed by Emergent BioSolutions and has been in clinical trails for lymphoma and Chronic Lymphocytic Leukemia (CLL).